amiodarone has been researched along with Diabetes Mellitus in 11 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This post hoc analysis evaluated efficacy and safety of dronedarone in atrial fibrillation (AF) and atrial flutter (AFL) patients with/without diabetes." | 9.51 | Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies. ( Bigot, G; Bunch, TJ; Handelsman, Y; Konigsberg, L; Kowey, PR; Rodbard, HW; Steinberg, BA; Thind, M; Wieloch, M, 2022) |
| "This post hoc analysis evaluated efficacy and safety of dronedarone in atrial fibrillation (AF) and atrial flutter (AFL) patients with/without diabetes." | 5.51 | Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies. ( Bigot, G; Bunch, TJ; Handelsman, Y; Konigsberg, L; Kowey, PR; Rodbard, HW; Steinberg, BA; Thind, M; Wieloch, M, 2022) |
| "We included 303 consecutive patients with amiodarone therapy for cardiac arrhythmias (260 with atrial fibrillation and 43 with ventricular arrhythmias)." | 3.77 | Determinants and outcome of amiodarone-associated thyroid dysfunction. ( Ahmed, S; Links, TP; Van Gelder, IC; Van Veldhuisen, DJ; Wiesfeld, AC, 2011) |
| "ICD therapy did not reduce the risk of sudden cardiac death in HFrEF patients with diabetes (HR = 0." | 2.90 | Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. ( Dewan, P; Jhund, PS; Kristensen, SL; Køber, L; McMurray, JJV; Petrie, MC; Rørth, R, 2019) |
| "Sudden cardiac death was observed in 16 patients, 8 patients in each group." | 2.72 | Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study. ( Crijns, HJ; Hagens, VE; Rienstra, M; Van Gelder, IC; Van Veldhuisen, DJ, 2006) |
| "Amiodarone was the most widely used active compound (82%) and apparently the most effective." | 1.39 | [Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs]. ( Alegret, JM; Freire, F; Romero-Menor, C; Viñolas, X, 2013) |
| "The average time to recurrence of AF after RFCA was 9." | 1.38 | Prediction of long-term outcomes of catheter ablation of persistent atrial fibrillation by parameters of preablation DC cardioversion. ( Ban, JE; Choi, JI; Kang, JH; Kim, MN; Kim, S; Kim, YH; Lee, DI; Lim, HE; Park, SW; Park, YM, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Handelsman, Y | 1 |
| Bunch, TJ | 1 |
| Rodbard, HW | 1 |
| Steinberg, BA | 1 |
| Thind, M | 1 |
| Bigot, G | 1 |
| Konigsberg, L | 1 |
| Wieloch, M | 1 |
| Kowey, PR | 1 |
| Rørth, R | 1 |
| Dewan, P | 1 |
| Kristensen, SL | 1 |
| Jhund, PS | 1 |
| Petrie, MC | 1 |
| Køber, L | 1 |
| McMurray, JJV | 1 |
| Guo, X | 1 |
| Zhang, Y | 1 |
| Xu, G | 1 |
| Zhou, X | 1 |
| Li, L | 1 |
| Tang, B | 1 |
| Zebis, LR | 1 |
| Christensen, TD | 1 |
| Thomsen, HF | 1 |
| Hjortdal, VE | 1 |
| Ahmed, S | 1 |
| Van Gelder, IC | 2 |
| Wiesfeld, AC | 1 |
| Van Veldhuisen, DJ | 2 |
| Links, TP | 1 |
| Kang, JH | 1 |
| Lee, DI | 1 |
| Kim, S | 1 |
| Kim, MN | 1 |
| Park, YM | 1 |
| Ban, JE | 1 |
| Choi, JI | 1 |
| Lim, HE | 1 |
| Park, SW | 1 |
| Kim, YH | 1 |
| Viñolas, X | 1 |
| Freire, F | 1 |
| Romero-Menor, C | 1 |
| Alegret, JM | 1 |
| Jung, W | 1 |
| Meyerfeldt, U | 1 |
| Birkemeyer, R | 1 |
| Hagens, VE | 1 |
| Rienstra, M | 1 |
| Crijns, HJ | 1 |
| Wartofsky, L | 1 |
| Burman, KD | 1 |
| Mizon, JP | 1 |
| Rosa, A | 1 |
| Betermiez, P | 1 |
| Sevestre, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Placebo-controlled,Double-blind,Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (AF/AFL)[NCT00174785] | Phase 3 | 4,628 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| EURopean Trial In Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)[NCT00259428] | Phase 3 | 615 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm (ADONIS)[NCT00259376] | Phase 3 | 629 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| Dual Shock Versus Single Shock Synchronized External Direct Current Cardioversion for Atrial Fibrillation - A Double-blinded Randomized Trial[NCT03943693] | Phase 4 | 100 participants (Actual) | Interventional | 2019-04-01 | Terminated (stopped due to Poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The considered event is cardiovascular death, as assessed by the blinded adjudication of the Steering Committee. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 63 |
| Placebo | 90 |
The considered event is cardiovascular death, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 65 |
| Placebo | 94 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 116 |
| Placebo | 139 |
The considered event is the first hospitalization for cardiovascular reason, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 675 |
| Placebo | 859 |
The primary event is the first hospitalization for cardiovascular reason or death from any cause, whichever is earlier, as assessed by the investigator. The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 734 |
| Placebo | 917 |
2 reviews available for amiodarone and Diabetes Mellitus
| Article | Year |
|---|---|
Atrial arrhythmias after cardiac surgery in patients with diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgic | 2006 |
Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome".
Topics: Adult; Age Factors; Aged; Amiodarone; Animals; Anorexia Nervosa; Contrast Media; Diabetes Mellitus; | 1982 |
4 trials available for amiodarone and Diabetes Mellitus
| Article | Year |
|---|---|
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Hum | 2022 |
Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction.
Topics: Aged; Amiodarone; Cause of Death; Death, Sudden, Cardiac; Defibrillators, Implantable; Diabetes Mell | 2019 |
Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Bypass; Coronary Arte | 2008 |
Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2006 |
5 other studies available for amiodarone and Diabetes Mellitus
| Article | Year |
|---|---|
[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; China; Comor | 2014 |
Determinants and outcome of amiodarone-associated thyroid dysfunction.
Topics: Adult; Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Databases, Factu | 2011 |
Prediction of long-term outcomes of catheter ablation of persistent atrial fibrillation by parameters of preablation DC cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Catheter Ablation; C | 2012 |
[Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Mass Index; Comorbidity; Diabete | 2013 |
[Neuropathy and cerebellar syndrome induced by amiodarone].
Topics: Amiodarone; Benzofurans; Cerebellar Diseases; Coronary Disease; Diabetes Mellitus; Humans; Lipids; L | 1985 |